Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oncology and immuno-oncology therapies. Headquartered in Boston, Massachusetts, Xenetic leverages its proprietary drug delivery platforms to enhance the performance of existing therapeutic agents and develop novel treatments with improved safety and efficacy profiles. The company’s primary objective is to address unmet medical needs in cancer and infectious disease by extending drug half-life, improving bioavailability and reducing toxicity through innovative molecular conjugation technologies.
At the core of Xenetic’s pipeline is PolyXen™, a platform designed to optimize therapeutic proteins and small molecules via non-covalent, reversible conjugation with low-molecular-weight, FDA-approved polysaccharides. Two lead product candidates illustrate the platform’s potential: PodDox™, a locoregional formulation of paclitaxel designed for intraperitoneal administration in ovarian cancer; and XBIO-101 (recombinant human hyaluronidase), intended to transiently enhance tissue permeability and facilitate the delivery of chemotherapeutics or biologics. In addition to oncology, Xenetic is exploring the utility of PolyXen in anti-infective therapies to improve penetration of antibiotic agents in resistant bacterial infections.
Founded in 2005 as a spin-out from a UK-based biotechnology group, Xenetic Biosciences has undergone strategic evolution from early research collaborations to a fully integrated development organization. Over the years, the company has entered into partnerships with global pharmaceutical firms to license its conjugation technology and co-develop pipeline candidates. Xenetic’s commitment to regulatory rigor is evidenced by completed phase 1 and phase 2 studies, and ongoing clinical trials aimed at validating safety, pharmacokinetics and therapeutic benefit in targeted patient populations.
Serving markets in North America, Europe and Asia through a combination of direct operations and partner networks, Xenetic Biosciences is led by CEO Robert Hoffman, whose two decades of experience span biotech innovation, clinical development and corporate strategy. Supported by a management team with expertise in regulatory affairs, translational research and commercial planning, Xenetic continues to advance its proprietary platforms toward late-stage development and seeks to forge additional alliances to accelerate the delivery of next-generation therapies to patients worldwide.
AI Generated. May Contain Errors.
Free XBIO Stock Alerts